TRIAL DETAIL
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 04/01/2010 |
Age of Trial (yrs) 13.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + MEK inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CBKM120B2101, 2009-017157-35 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals
+1(800)340-6843 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Inclusion Criteria: histologically/ cytologically confirmed, advanced non resectable solid tumors Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0 |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
10945 Le Conte Ave. |
Los Angeles |
CA |
90095 |
USA |
|
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
610 University Ave |
Toronto |
ON |
M5G 2M9 |
Canada |
|
Herestraat 49 |
Leuven |
Belgium |
|||
119-129 |
Barcelona |
08035 |
Spain |
||
Bellinzona |
Switzerland |
||||
Sevilla |
Andalucia |
41013 |
Spain |